RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
RenovoRx today announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461).
RenovoRx Launches Post-Marketing Study to Advance Real-World Use of RenovoCath Device
RenovoRx’s PanTheR study evaluates the RenovoCath device’s long-term safety and effectiveness in treating solid tumors through real-world data collection.